jmf123
Oct 3, 12:40 AM
$ICU The company has been reported as saying there is a
$25–
$33 billion potential annual U.S. addressable market across multiple SCD indications, including adult acute kidney injury (AKI), cardiorenal syndrome, ARDS, hepatorenal syndrome, and patients receiving LVAD support. If ICU can capture just 5%, that would reflect somewhere in
$1.2-
$1.5 Billion in sales revenues. A valuation at 4-5 x revenues would be
$5-
$8.3 Billion market cap. Today we stand at around
$16M market cap. Even if the company has to dilute to fund operations, the upside is ridiculous. Assuming 100% dilution, going to 8M shares, a
$5 billion market cap would equal a share price of
$625. HELLO!
0 replies
